70280-03-4

Basic information

• Product Name: N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE
• Synonyms: d-alpha-glutamine,n-(n-acetyl-4-o-(2-(acetylamino)-2-deoxy-beta-d-glucopyrano;glucosaminylmuramyldipeptide;n-acetyl-beta-glucosaminyl-(1-4)-n-acetylmuramyl-l-alanyl-d-isoglutamine;n-acetyl-beta-glucosaminyl-n-acetylmuramyl-alanylisoglutamine;n-acetylglucosaminyl-n-acetylmuramyl-l-alanyl-d-isoglutamine;syl)muramoyl)-l-alanyl-;4-(2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSYL)-N-ACETYLMURAMYL-L-ALA-D-GLU AMIDE;D-GLCNAC-BETA-(1->4)-N-ACETYLMURAMYL-L-ALA-D-ISOGLUTAMINE
• CAS NO: 70280-03-4
• Molecular Formula: C27H45N5O16
• Molecular Weight: 695.67
• Mol File: 70280-03-4.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 1270.1°Cat760mmHg
• Flash Point: 721.9°C
• Appearance: /
• Density: 1.47g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: −20°C
• CAS DataBase Reference: N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE(70280-03-4)
• EPA Substance Registry System: N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE(70280-03-4)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22
• Safety Statements: 36/37
• WGK Germany: 3
• RTECS: MA2275230
• Hazardous Substances Data: 70280-03-4(Hazardous Substances Data)

Usage

Description

N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE, also known as MDP (Muramyl Dipeptide) or N-acetyl-β-D-glucosaminyl-(1→4)-N-acetylmuramyl-L-alanyl-D-isoglutamine, is a synthetic analog of a bacterial cell wall component. It is a small molecule with immunostimulatory properties that can modulate the immune system and has been used in various medical applications.

Uses

1. Used in Autoimmune Disease Treatment:
N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE is used as an immunomodulator or immunostimulant for the treatment of various autoimmune diseases. It helps in regulating the immune system and reducing the severity of autoimmune conditions.
2. Used in Hospital-Related Infections:
In the medical industry, N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE is used as an immunostimulant to help the body fight against hospital-related infections. Its immunostimulatory properties aid in enhancing the body's defense mechanisms against bacterial and fungal infections.
3. Used in Psoriasis Treatment:
N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE is used as a treatment for psoriasis, a chronic skin condition characterized by the rapid growth and shedding of skin cells. Its immunomodulatory effects help in reducing inflammation and improving the symptoms of psoriasis.
4. Used in Cervical Precancerous Lesions Treatment:
In the field of gynecology, N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE is used as a treatment for cervical precancerous lesions. Its immunostimulatory properties help in strengthening the body's immune response against precancerous cells, potentially preventing the development of cervical cancer.
5. Used in Ophthalmic Keratitis Treatment:
In the field of ophthalmology, N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE is used for the treatment of ophthalmic keratitis caused by herpes. Its immunomodulatory effects help in reducing inflammation and promoting the healing of the cornea.
6. Used as an Adjuvant in Vaccine Development:
N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE is used as an adjuvant in the development of vaccines, particularly for highly purified protein antigens. It stimulates the induction of CD8+ T-cell response, enhancing the body's immune response to the vaccine.
7. Used in Reducing Inflammation and Inhibiting Systemic Response to Endotoxin:
N-ACETYL-D-GLUCOSAMINYL-(BETA1,4)-N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE has been found to reduce the levels of TNF-α, IL-1α, and hypoglycemia induced by LPS administration. It also inhibits the systemic response to endotoxin, making it a potential therapeutic agent for conditions involving inflammation and endotoxin exposure.
Brand Name: Likopid

Originator

Peptech (Australia)

InChI:InChI=1/C27H45N5O16/c1-10(25(44)32-14(24(28)43)5-6-18(39)40)29-26(45)11(2)46-22(15(7-33)30-12(3)36)23(16(38)8-34)48-27-19(31-13(4)37)21(42)20(41)17(9-35)47-27/h7,10-11,14-17,19-23,27,34-35,38,41-42H,5-6,8-9H2,1-4H3,(H2,28,43)(H,29,45)(H,30,36)(H,31,37)(H,32,44)(H,39,40)/t10-,11+,14+,15-,16+,17+,19+,20+,21+,22+,23+,27-/m0/s1